Regeneron Pharma

REGN

805.9300.30% ( +2.450 )

Closed: Aug 17, 16:00:00 (EDT)

2026-W332026-08-10

REGN.US Weekly Report · 2026-W33

Weekly Price Action

Regeneron Pharmaceuticals closed the week at $803.48, representing a 2.43% gain from last week’s close of $784.36. Intra-week volatility was modest at 1.75% (high $806.54 vs low $792.57), characterizing a steady upward drift with minor fluctuations. Weekly trading volume reached 4.256 million shares, below the 60-day average, indicating somewhat compressed liquidity and weakening market participation.

Valuation and Earnings

The current P/E multiple stands at 19.62x, positioned near the 41st percentile of the 3-year range, suggesting a below-median valuation. Price-to-book ratio is 2.68x. Latest quarterly results show Q2 2026 EPS of $1.23, down 4.53% year-over-year but substantially improved sequentially from Q1’s $0.675. Operating revenue of $4.291 billion grew 16.73% year-over-year, a healthy trajectory; net profit of $1.297 billion declined 6.81% year-over-year, indicating profit growth lagging revenue growth. This divergence suggests margin or cost management headwinds.

Consensus 2026 EPS forecast stands at $60.89, with current quarterly annualized results trailing this target. The most recent five forecasting snapshots show stable institutional expectations with no material upward or downward revisions, signaling consensus stability.

Capital Flows

Mid-cap funds registered modest net inflow of 184.27 (inflows 982.79 vs outflows 798.52); retail participation showed small net inflow of 86.11 (inflows 1,623.40 vs outflows 1,537.29). Overall capital posture is net-positive but tepid in magnitude, reflecting neutral-to-weak sentiment without strong directional commitment.

Institutional Opinion

Current analyst coverage spans 27 institutions: 14 strong buy, 4 buy, 9 hold, 4 reduce. The bullish faction (18 combined) substantially outnumbers bears (4), ranking the stock 10th within its peer group. Consensus target price of $833.65 implies 3.76% upside from current levels, though the ratings snapshot as of August 13 carries a lag consideration.

Weekly News Summary

Key developments this week centered on partnership progress and litigation headwinds:

Litigation risk emerged as a headline focal point, while pipeline progress (Libtayo’s Canadian approval) and collaboration expansion (deepened CTMX partnership) underscore underlying operational momentum. The market’s caution reflects concern over profitability quality: despite 17% revenue growth, the stock faces margin compression pressure, signaling skepticism about bottom-line sustainability.

Tensions and Coherence

Depressed valuation (P/E near 41st percentile) aligns logically with overwhelming institutional bullishness (78% buy-rated), both pointing toward value merit. However, tepid capital inflow diverges from the 2.43% weekly price gain—stronger bullish conviction would typically attract more forceful fund deployment. Compressed trading volume reinforces this disconnect, weakening the persuasiveness of the upside case. Litigation risk, now in sharper focus, remains under-priced in current ratings. Earnings headwinds (EPS down 4.53% year-over-year) create tension with optimistic analyst views; the trajectory of profitability in coming quarters will be a critical litmus test.